{"id":9778,"date":"2025-10-13T06:34:33","date_gmt":"2025-10-13T11:34:33","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=9778"},"modified":"2025-10-13T07:34:38","modified_gmt":"2025-10-13T12:34:38","slug":"nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/ja\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","title":{"rendered":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u30012025\u5e74\u7c73\u56fd\u773c\u79d1\u5b66\u4f1a\u5e74\u6b21\u7dcf\u4f1a\u3067\u306e\u8907\u6570\u767a\u8868\u3092\u767a\u8868"},"content":{"rendered":"
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\r\n\t\t\t\t\t\t\t\t
\r\n\r\n\t\t\t\t\r\n\t\t\t\t
\r\n\t\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u30c0\u30e9\u30b9<\/span>,\u00a02025\u5e7410\u670813\u65e5<\/span>\u00a0 \u2014\u00a0\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u682a\u5f0f\u4f1a\u793e<\/a>, \u7db2\u819c\u5909\u6027\u306b\u3088\u308b\u5149\u53d7\u5bb9\u4f53\u55aa\u5931\u304a\u3088\u3073\u8996\u899a\u969c\u5bb3\u306e\u60a3\u8005\u5411\u3051\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u65b0\u898f\u6cbb\u7642\u6cd5\u306e\u958b\u767a\u304a\u3088\u3073\u5546\u696d\u5316\u306b\u53d6\u308a\u7d44\u3080\u30d0\u30a4\u30aa\u30c6\u30af\u30ce\u30ed\u30b8\u30fc\u4f01\u696d\u3067\u3042\u308b \u306f\u672c\u65e5\u3001\u00a0\u30a2\u30e1\u30ea\u30ab\u773c\u79d1\u5b66\u4f1a<\/i>\u00a0(AAO) 2025\u5e74\u5e74\u6b21\u7dcf\u4f1a<\/a>, 2025\u5e7410\u670818\u65e5\uff5e20\u65e5\u306b\u30d5\u30ed\u30ea\u30c0\u5dde\u30aa\u30fc\u30e9\u30f3\u30c9\u3067\u958b\u50ac\u3055\u308c\u308b\u307b\u304b\u3001\u00a0Eyecelerator@AAO 2025<\/a><\/i>,<\/i>\u00a02025\u5e7410\u670816\u65e5\u3001\u540c\u3058\u304f\u30aa\u30fc\u30e9\u30f3\u30c9\u306b\u3066\u3002.<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u793e\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u304a\u3088\u3073\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u306b\u3088\u308b\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u60a3\u8005\u3092\u5bfe\u8c61\u3068\u3057\u305f\u3001\u72ec\u81ea\u306e\u591a\u7279\u6027\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3088\u308b\u8996\u529b\u56de\u5fa9\u6280\u8853\u3092\u5c55\u793a\u3059\u308b\u4e88\u5b9a\u3067\u3059\u3002\u3053\u308c\u3089\u306e\u75be\u60a3\u306f\u3044\u305a\u308c\u3082\u3001\u73fe\u5728\u627f\u8a8d\u3055\u308c\u3066\u3044\u308b\u6cbb\u7642\u6cd5\u304c\u306a\u3044\u3001\u751f\u6d3b\u306b\u652f\u969c\u3092\u304d\u305f\u3059\u6df1\u523b\u306a\u75c5\u6c17\u3067\u3059\u3002.<\/p>

\u30d7\u30ec\u30bc\u30f3\u30c6\u30fc\u30b7\u30e7\u30f3\u306e\u8a73\u7d30\uff1a<\/p>

\u30bf\u30a4\u30c8\u30eb\uff1a<\/b>\u00a0“Nanoscope Therapeutics Company Showcase” (Eyecelerator @AAO 2025)
<\/i>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a\u00a0<\/b>\u5f8c\u90e8\/\u7db2\u819c
<\/i>\u65e5\u4ed8\uff0f\u6642\u9593:<\/b>\u00a02025\u5e7410\u670816\u65e5\uff08\u6728\uff09\u5348\u5f8c1\u664240\u5206\uff5e1\u664245\u5206\uff08\u7c73\u56fd\u6771\u90e8\u590f\u6642\u9593\uff09
\u4f4d\u7f6e\uff1a<\/b>\u00a0W230
\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>\u30b5\u30df\u30e5\u30a8\u30eb\u30fb\u30d0\u30ed\u30f3\u533b\u5e2b\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u6700\u9ad8\u533b\u7642\u8cac\u4efb\u8005<\/a><\/p>

\u30bf\u30a4\u30c8\u30eb\uff1a<\/b>\u00a0“152-Week REMAIN Data from Extended Analysis of MCO-010 RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa”
<\/i>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a<\/b>\u00a0\u7b2cXI\u7ae0\uff1a\u6700\u65b0\u306e\u52d5\u5411\u3001\u30d1\u30fc\u30c8II
\u65e5\u4ed8\uff0f\u6642\u9593:<\/b>\u00a02025\u5e7410\u670818\u65e5\uff08\u571f\uff09\u5348\u524d8\u664211\u5206\uff5e8\u664218\u5206\uff08\u7c73\u56fd\u6771\u90e8\u590f\u6642\u9593\uff09
\u4f4d\u7f6e\uff1a<\/b>\u00a0W415 \u30d0\u30ec\u30f3\u30b7\u30a2
\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a<\/b>\u00a0\u30a2\u30ec\u30f3\u30fbC\u30fb\u30db\u30fc\u533b\u5e2b\uff08\u533b\u5b66\u535a\u58eb\u3001\u7c73\u56fd\u5916\u79d1\u5c02\u9580\u533b\u3001\u7c73\u56fd\u7db2\u819c\u5916\u79d1\u5c02\u9580\u533b\uff09\u3001\u30a6\u30a3\u30eb\u30ba\u773c\u79d1\u75c5\u9662\u4e3b\u4efb\u5916\u79d1\u533b\u517c\u7db2\u819c\u7814\u7a76\u90e8\u9577\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u6700\u9ad8\u533b\u7642\u9867\u554f<\/a>.<\/p>

\u30bf\u30a4\u30c8\u30eb\uff1a<\/b>\u00a0“Visual Improvement Across Multiple Assessments with MCO-010 Optogenetic Therapy for Stargardt Disease”
<\/i>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a<\/b>\u00a0\u30dd\u30b9\u30bf\u30fc\u30d1\u30cd\u30eb\u30c7\u30a3\u30b9\u30ab\u30c3\u30b7\u30e7\u30f3\uff1a\u7db2\u819c\u3001\u785d\u5b50\u4f53
\u65e5\u4ed8\uff0f\u6642\u9593:<\/b>\u00a02025\u5e7410\u670818\u65e5\uff08\u571f\uff09\u5348\u5f8c1\u664245\u5206\uff5e\u5348\u5f8c2\u664215\u5206\uff08\u7c73\u56fd\u6771\u90e8\u590f\u6642\u9593\uff09
\u4f4d\u7f6e\uff1a\u00a0<\/b>\u30db\u30fc\u30ebWB4\u3001\u30b9\u30c6\u30fc\u30b7\u30e7\u30f31
\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a<\/b>\u00a0\u30b1\u30cd\u30b9\u30fbC\u30fb\u30d5\u30a1\u30f3\u533b\u5e2b\u3001\u30c6\u30ad\u30b5\u30b9\u7db2\u819c\u30b3\u30f3\u30b5\u30eb\u30bf\u30f3\u30c8<\/a><\/p>

\u30bf\u30a4\u30c8\u30eb:<\/i><\/b>\u00a0\u00a0“Optogenetic Therapy in Adults with Retinitis Pigmentosa and Stargardt Disease”
<\/i>\u30bb\u30c3\u30b7\u30e7\u30f3\uff1a<\/b>\u00a0\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6cbb\u7642\u30a2\u30d7\u30ed\u30fc\u30c1
\u65e5\u4ed8\uff0f\u6642\u9593:<\/b>\u00a02025\u5e7410\u670820\u65e5\uff08\u6708\uff09\u5348\u524d8\u664230\u5206\uff5e8\u664245\u5206\uff08\u7c73\u56fd\u6771\u90e8\u590f\u6642\u9593\uff09
\u4f4d\u7f6e\uff1a<\/b>\u00a0W311E
\u30d7\u30ec\u30bc\u30f3\u30bf\u30fc\uff1a\u00a0<\/b>\u30b5\u30de\u30ec\u30f3\u30c9\u30e9\u30fb\u30e2\u30cf\u30f3\u30c6\u30a3\u535a\u58eb\u3001\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u9577\u517c\u6700\u9ad8\u79d1\u5b66\u8cac\u4efb\u8005<\/a>; \u305d\u3057\u3066\u00a0\u30b9\u30c6\u30a3\u30fc\u30d6\u30f3\u30fb\u30c4\u30a1\u30f3\u533b\u5e2b\uff08\u533b\u5b66\u535a\u58eb\u3001\u30b3\u30ed\u30f3\u30d3\u30a2\u5927\u5b66\u30a2\u30fc\u30d3\u30f3\u30b0\u533b\u7642\u30bb\u30f3\u30bf\u30fc\uff09<\/a>.<\/p>

“We look forward to sharing and discussing the latest MCO-010 data at AAO and Eyecelerator 2025,” said\u00a0\u30b9\u30e9\u30cb\u30e3\u30fb\u30d0\u30bf\u30c1\u30e3\u30ea\u30e4\u3001\u6700\u9ad8\u7d4c\u55b6\u8cac\u4efb\u8005<\/a>. “These presentations underscore the continued strength of our clinical and regulatory foundation. With the rolling BLA for RP now underway and five new orphan designations granted by the European Medicines Agency, we are driving strong global momentum toward bringing MCO-010 to patients affected by blinding retinal diseases.”<\/p>

MCO\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306b\u3064\u3044\u3066
<\/b>MCO\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\u3001\u5730\u56f3\u72b6\u840e\u7e2e\u75c7\uff08GA\uff09\u306a\u3069\u306e\u5149\u53d7\u5bb9\u4f53\u5909\u6027\u75c7\u60a3\u8005\u306e\u8996\u529b\u56de\u5fa9\u3092\u76ee\u7684\u3068\u3057\u305f\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u5358\u56de\u6295\u4e0e\u306e\u785d\u5b50\u4f53\u5185\u6cbb\u7642\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002MCO\u306f\u3001\u9ad8\u5bc6\u5ea6\u306e\u53cc\u6975\u7db2\u819c\u7d30\u80de\u3092\u6d3b\u6027\u5316\u3057\u3066\u5149\u611f\u53d7\u6027\u3092\u6301\u305f\u305b\u308b\u3053\u3068\u3067\u3001\u5149\u53d7\u5bb9\u4f53\u6b7b\u5f8c\u306b\u6b8b\u5b58\u3059\u308b\u8996\u899a\u56de\u8def\u3092\u6d3b\u7528\u3057\u307e\u3059\u3002MCO\u6cbb\u7642\u306f\u3001\u907a\u4f1d\u5b50\u691c\u67fb\u3001\u4fb5\u8972\u7684\u306a\u624b\u8853\u3001\u307e\u305f\u306f\u7e70\u308a\u8fd4\u3057\u6295\u4e0e\u3092\u5fc5\u8981\u3068\u3057\u306a\u3044\u305f\u3081\u3001\u65e2\u5b58\u306e\u7db2\u819c\u8a3a\u7642\u30ef\u30fc\u30af\u30d5\u30ed\u30fc\u5185\u3067\u5e45\u5e83\u3044\u60a3\u8005\u306b\u9069\u7528\u53ef\u80fd\u3067\u3059\u3002.<\/p>

\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306b\u3064\u3044\u3066
<\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u306f\u3001\u7db2\u819c\u5909\u6027\u75be\u60a3\u306b\u3088\u308a\u5931\u660e\u3057\u305f\u6570\u767e\u4e07\u4eba\u306e\u60a3\u8005\u306e\u305f\u3081\u306b\u3001\u75be\u60a3\u3092\u554f\u308f\u306a\u3044\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u5149\u907a\u4f1d\u5b66\u7684\u6cbb\u7642\u6cd5\u3092\u958b\u767a\u3057\u3066\u3044\u307e\u3059\u3002\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\uff08NCT04945772<\/a>\uff09\u3001FDA\u3078\u306eBLA\u7533\u8acb\u304c\u9806\u6b21\u958b\u59cb\u3055\u308c\u3066\u3044\u307e\u3059\u3002\u627f\u8a8d\u3055\u308c\u308c\u3070\u3001MCO-010\u306f\u907a\u4f1d\u5b50\u691c\u67fb\u3092\u5fc5\u8981\u3068\u305b\u305a\u3001\u8a3a\u7642\u6240\u30671\u56de\u6ce8\u5c04\u3059\u308b\u3060\u3051\u3067\u6295\u4e0e\u3067\u304d\u308b\u305f\u3081\u3001RP\u60a3\u8005\u306e\u6a19\u6e96\u6cbb\u7642\u3068\u306a\u308b\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u540c\u793e\u306f\u307e\u305f\u3001\u30b9\u30bf\u30fc\u30ac\u30eb\u30c8\u75c5\uff08SD\uff09\uff08NCT05417126<\/a>\uff09\u3092\u958b\u59cb\u3057\u3001\u00a0\u30d5\u30a7\u30fc\u30ba3\u767b\u9332\u8a66\u9a13<\/a>\u00a02025\u5e74\u306b\u3001MCO-010\u306f\u3001\u7db2\u819c\u8272\u7d20\u5909\u6027\u75c7\uff08RP\uff09\u3068\u30b9\u30bf\u30d5\u30a3\u30f3\u30fb\u30c7\u30a3\u30d5\u30a3\u30b7\u30eb\uff08SD\uff09\u306e\u4e21\u65b9\u3067FDA\u306e\u30d5\u30a1\u30b9\u30c8\u30c8\u30e9\u30c3\u30af\u304a\u3088\u3073\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3092\u53d7\u3051\u3001SD\u3067\u306fRMAT\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u307e\u305f\u3001\u975e\u75c7\u5019\u6027\u304a\u3088\u3073\u75c7\u5019\u6027\u306e\u687f\u4f53\u30fb\u9310\u4f53\u512a\u4f4d\u6027\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3001\u9ec4\u6591\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u3092\u5bfe\u8c61\u3068\u3059\u308bEMA\u306e\u5e0c\u5c11\u75be\u75c5\u7528\u533b\u85ac\u54c1\u6307\u5b9a\u3082\u53d7\u3051\u3066\u3044\u307e\u3059\u3002\u5730\u7406\u7684\u840e\u7e2e\uff08GA\uff09\u306b\u304a\u3051\u308bMCO\u306e\u7b2c2\u76f8\u30d7\u30ed\u30b0\u30e9\u30e0\u306f\u30012025\u5e74\u672b\u307e\u3067\u306b\u958b\u59cb\u3055\u308c\u308b\u4e88\u5b9a\u3067\u3059\u3002IND\u7533\u8acb\u6e96\u5099\u304c\u6574\u3063\u3066\u3044\u308b\u305d\u306e\u4ed6\u306e\u30d7\u30ed\u30b0\u30e9\u30e0\u306b\u306f\u3001\u30ec\u30fc\u30d0\u30fc\u5148\u5929\u6027\u9ed2\u5185\u969c\uff08LCA\uff09\u304c\u3042\u308a\u307e\u3059\u3002.<\/p>

\u63a5\u89e6\uff1a
<\/b>\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9
(817) 857-1186
PR@nanostherapeutics.com<\/a><\/p>

\u51fa\u5178 \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\r\n\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t<\/div>\r\n\t\t\t<\/section>\r\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0Oct. 13, 2025\u00a0 —\u00a0Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced multiple presentations at the\u00a0American Academy of Ophthalmology\u00a0(AAO) 2025 Annual Meeting, to be held October 18-20, 2025 in Orlando, FL, as well as at\u00a0Eyecelerator@AAO 2025,\u00a0on October 16, 2025, also in Orlando. Nanoscope will showcase the vision-restoring proprietary Multi-Characteristic Opsin (MCO) platform for patients with severe vision loss from retinitis pigmentosa (RP) and Stargardt disease (SD), both debilitating conditions with no currently approved treatments. Presentation Details: Title:\u00a0“Nanoscope Therapeutics Company Showcase” (Eyecelerator @AAO 2025)Session:\u00a0Posterior\/RetinalDate \/ Time:\u00a0Thursday, October 16, 2025 | 1:40-1:45 p.m. […]<\/p>\n","protected":false},"author":6,"featured_media":8971,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-9778","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/ja\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/ja\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-13T11:34:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T12:34:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"3\u5206\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting\",\"datePublished\":\"2025-10-13T11:34:33+00:00\",\"dateModified\":\"2025-10-13T12:34:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"},\"wordCount\":605,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"ja\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\",\"name\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"datePublished\":\"2025-10-13T11:34:33+00:00\",\"dateModified\":\"2025-10-13T12:34:38+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg\",\"width\":1200,\"height\":242},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2025\\\/10\\\/13\\\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7c73\u56fd\u773c\u79d1\u5b66\u4f1a2025\u5e74\u5e74\u6b21\u7dcf\u4f1a\u3067\u306e\u8907\u6570\u767a\u8868\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/ja\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","og_locale":"ja_JP","og_type":"article","og_title":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/ja\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2025-10-13T11:34:33+00:00","article_modified_time":"2025-10-13T12:34:38+00:00","og_image":[{"width":1200,"height":242,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"\u57f7\u7b46\u8005":"Nanoscope Therapeutics","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"3\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting","datePublished":"2025-10-13T11:34:33+00:00","dateModified":"2025-10-13T12:34:38+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"},"wordCount":605,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","url":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e\u3001\u7c73\u56fd\u773c\u79d1\u5b66\u4f1a2025\u5e74\u5e74\u6b21\u7dcf\u4f1a\u3067\u306e\u8907\u6570\u767a\u8868\u3092\u767a\u8868 - \u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","datePublished":"2025-10-13T11:34:33+00:00","dateModified":"2025-10-13T12:34:38+00:00","description":"\u5f53\u793e\u306e\u591a\u6a5f\u80fd\u30aa\u30d7\u30b7\u30f3\uff08MCO\uff09\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306f\u3001\u81e8\u5e8a\u8a66\u9a13\u306b\u304a\u3044\u3066\u91cd\u5ea6\u306e\u8996\u529b\u55aa\u5931\u3092\u4f34\u3046\u7db2\u819c\u75be\u60a3\u60a3\u8005\u306e\u8996\u529b\u3092\u56de\u5fa9\u3055\u305b\u308b\u80fd\u529b\u3092\u5b9f\u8a3c\u3057\u305f\u521d\u306e\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u3067\u3059\u3002Nanoscope\u793e\u306f\u3001\u907a\u4f1d\u5b50\u306b\u4f9d\u5b58\u3057\u306a\u3044\u3001\u5e83\u7bc4\u56f2\u306e\u30b9\u30da\u30af\u30c8\u30eb\u3001\u9ad8\u901f\u5fdc\u7b54\u6027\u3001\u8d85\u9ad8\u611f\u5ea6\u3092\u5099\u3048\u305f\u3001\u8996\u529b\u56de\u5fa9\u306e\u305f\u3081\u306e\u6700\u521d\u3067\u552f\u4e00\u306e\u5149\u907a\u4f1d\u5b66\u6280\u8853\u3067\u3042\u308bMCO-010\u3092\u958b\u767a\u3057\u307e\u3057\u305f\u3002.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/06\/NSCOPE_nu_Logo_Horizontal_2Color_1200px.jpg","width":1200,"height":242},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2025\/10\/13\/nanoscope-therapeutics-announces-multiple-presentations-at-the-american-academy-of-ophthalmology-2025-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics Announces Multiple Presentations at the American Academy of Ophthalmology 2025 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9","description":"\u5e0c\u671b\u306e\u5149\u3092\u53d6\u308a\u623b\u3059","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9\u793e","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"\u30ca\u30ce\u30b9\u30b3\u30fc\u30d7\u30fb\u30bb\u30e9\u30d4\u30e5\u30fc\u30c6\u30a3\u30af\u30b9"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9778","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/comments?post=9778"}],"version-history":[{"count":7,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9778\/revisions"}],"predecessor-version":[{"id":9786,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/posts\/9778\/revisions\/9786"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media\/8971"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/media?parent=9778"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/categories?post=9778"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/ja\/wp-json\/wp\/v2\/tags?post=9778"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}